In a study, published in the World Journal of Urology, researchers evaluated whether the expression of markers for cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2), and peri-tumoral lymphocytes (CD3, CD8) could provide insight into the development of urothelial tumors in neuro-urological patients with bladder cancer (NBC).
Lead author Floriane Michel and contributors retrieved tissue samples from patients with NBC from 15 medical centers in France. NBC samples were analyzed and compared to control samples from non neuro-urological patients with bladder cancer (NNBC) as well as samples from neuro-urological patients without bladder cancer (NB). Finally, the team utilized immunohistochemistry of tissue microarray sections to analyze the expression of CK7, CK14, CK20, GATA3, p53, Ki67, STAG2, CD3, and CD8 markers.
According to the report, tissue samples from a total of 124 patients were included in the study (NBC = 62; NNBC = 26; NB = 26). In the NBC group, muscle-invasive bladder cancer (MIBC) and squamous cell differentiation were observed in 52 (72.2%) and 9 (12.5%) patients, respectively. Furthermore, the expression of CK20 and GATA3 was significantly more frequent in NMIBC compared to MIBC (p = 0.015 and p <0.001); expression of CK20 and GATA3 was significantly more frequent in NBC compared to NNBC (p <0.001 and p = 0.010); and the expression of CK14, Ki67, CD3, and CD8 was significantly more frequent in NBC than in NNBC ((p = 0.005, p <0.001, p <0.001 and p <0.001). Lastly, the expression of CD3 and CD8 was similar between NBC and NB samples.
The authors concluded that patients with NBC had significantly higher expression of markers for basal differentiation, proliferation, and peri-tumoral lymphocytes compared to NNBC controls. They closed their article with the perspective that “these results suggest the aggressiveness of NBC and the role of chronic inflammation in the carcinogenesis of bladder cancer in neuro-urological patients.